Are you Dr. Uckun?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2848 Patton Rd
Roseville, MN 55113Phone+1 651-628-0098Fax+1 651-796-5378
Summary
- Dr. Fatih Uckun, MD is an oncologist in Roseville, Minnesota.
Publications & Presentations
PubMed
- 5 citationsTyrosine kinases in KMT2A/MLL-rearranged acute leukemias as potential therapeutic targets to overcome cancer drug resistance.Fatih M Uckun, Sanjive Qazi
Cancer Drug Resistance. 2022-01-01 - 25 citationsA Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.Fatih M. Uckun, Tara L. Lin, Alice S. Mims, Prapti Patel, Cynthia Lee
Cancers. 2021-08-15 - 12 citationsCD22ΔE12 as a molecular target for corrective repair using RNA trans-splicing: anti-leukemic activity of a rationally designed RNA trans-splicing molecule.Fatih M. Uckun, Sanjive Qazi, Hong Ma, Gregory H. Reaman, Lloyd G. Mitchell
Integrative Biology. 2015-02-10
Press Mentions
Oncotelic Appoints Fatih Uckun, M.D., Ph.D., as Chief Medical OfficerMay 3rd, 2022- Aptevo Therapeutics Reports in the Refereed Medical Journal Cancers That the Risk of Cytokine Release Syndrome Is Low for Blood Cancer Patients Treated with Its Bispecific Antibody APVO436October 26th, 2021
- Reven Holdings Announces First Patient Dosed in Double-Blind, Randomized, Multi-Institutional Phase 2 Clinical Trial Evaluating Its Lead Anti-Sepsis Drug Candidate RJX in Hospitalized High-Risk COVID-19 PatientsOctober 22nd, 2021
- Join now to see all
